Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,833
  • Shares Outstanding, K 4,085
  • Annual Sales, $ 7,310 K
  • Annual Income, $ -6,710 K
  • 60-Month Beta 2.72
  • Price/Sales 1.59
  • Price/Cash Flow 42.72
  • Price/Book 2.40
Trade CGIX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.10
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/18/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +7.21%
on 03/30/21
7.48 -38.37%
on 03/22/21
-1.90 (-29.19%)
since 02/26/21
3-Month
2.61 +76.63%
on 12/29/20
17.50 -73.66%
on 02/10/21
+1.90 (+70.11%)
since 12/28/20
52-Week
2.11 +118.73%
on 10/30/20
17.50 -73.66%
on 02/10/21
+1.53 (+49.68%)
since 03/27/20

Most Recent Stories

More News
UK - National Institute for Health and Care Excellence (NICE) Issues MedTech Innovation Briefing on 'Trublood®- Prostate' for Precision Non-invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'

/PRNewswire/ -- Datar Cancer Genetics, a world leading non-invasive cancer analytics and diagnostics company having its Research Head Quarters at Nasik, , announced the publication of the internationally...

CGIX : 4.61 (-2.33%)
National Institute for Health and Care Excellence (NICE) - UK Issues MedTech Innovation Briefing on 'Trublood(R)- Prostate' for Precision Non-invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'

LONDON, July 13, 2021 /PRNewswire/ -- Datar Cancer Genetics, a world leading non-invasive cancer analytics and diagnostics company, announced the publication of the internationally recognized MedTech Innovation...

CGIX : 4.61 (-2.33%)
Datar Cancer Genetics joins hands with U.S. based Iylon Precision Oncology to offer personalized Precision Oncology cancer treatment solutions

NASHIK, India, July 4, 2021

CGIX : 4.61 (-2.33%)
Precision Medicine Market Revenue to Cross USD 112 Bn by 2027: Global Market Insights Inc.

/PRNewswire/ -- According to the latest report , by Global Market Insights Inc., the  will cross by 2027. Various technological advancements in precision medicine will foster the market growth.

CGIX : 4.61 (-2.33%)
LLY : 243.50 (-0.75%)
FMI : 136.95 (-0.04%)
LH : 296.15 (+0.51%)
MDT : 131.31 (+0.48%)
NVS : 92.39 (+0.22%)
DGX : 141.80 (+0.40%)
Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis

Aimmune Therapeutics, a Nestle Health Science company developing pharmaceutical therapies to prevent, manage and treat food and metabolic-related diseases, including exocrine pancreatic insufficiency (EPI),...

AIMT : 34.49 (-0.29%)
CGIX : 4.61 (-2.33%)
ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes

Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data...

CGIX : 4.61 (-2.33%)
Prostate Cancer Diagnostics Market Size, Share, Trends, Analysis and Forecast 2027

The report on Prostate Cancer Diagnostics provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

DXD.VN : 0.040 (unch)
BIOC : 4.09 (+4.60%)
CGIX : 4.61 (-2.33%)
FMI : 136.95 (-0.04%)
GHDX : 63.44 (-0.69%)
MYGN : 31.63 (+1.22%)
OPK : 3.44 (-7.77%)
SIEGY : 78.1050 (-1.25%)
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and...

CGIX : 4.61 (-2.33%)
VYNT : 2.95 (unch)
Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...

CGIX : 4.61 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 4.92
1st Resistance Point 4.77
Last Price 4.61
1st Support Level 4.38
2nd Support Level 4.14
3rd Support Level 3.99

See More

52-Week High 17.50
Fibonacci 61.8% 11.62
Fibonacci 50% 9.80
Fibonacci 38.2% 7.99
Last Price 4.61
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar